Stanford is one of the trial sites; the work is being led by Michael McConnell, MD, professor of cardiovascular medicine.
“This is the first NIH trial to study prospectively a cardiovascular diagnostic imaging test for outcomes, which is a major change in paradigm,” said McConnell. “Usually diagnostic tests are compared to determine which makes the more accurate diagnosis without thinking about the downstream effects. This study takes the view that it’s how patients do that is ultimately most important.”
The PROMISE trial at Stanford is actively recruiting outpatients presenting to their doctor with chest pain who do not already have known coronary artery disease. Any physician with such a patient can page the PROMISE team at Stanford at (650) 723-8222 pager #27888 to receive further information regarding patient eligibility.
The imaging tests will be conducted at Stanford, but the care and treatment of the enrolled patients will remain with their personal physicians. The trial randomizes the patient between stress testing and coronary CT angiography, and provides those test results. The study will then keep track of the patient’s outcome in terms of developing heart disease, needing an invasive heart procedure or developing medical complications.
“With so many tests available to cardiologists and primary care doctors these days, the goal is to provide the evidence for which test leads to the best outcomes for patients,” McConnell said.
The national study is seeking to enroll 10,000 patients at more than 200 sites. Every year, 4 to 5 million patients have non-invasive tests to find out if the chest pain they are experiencing is caused by coronary artery disease.
Other Stanford co-investigators include Dominik Fleishmann, MD, professor of radiology; Sandra Tsai, MD, clinical assistant professor of internal medicine; and cardiology fellows Ian Rogers, MD, and Catherine Dao, MD.